Neurostem®-Ad
Delirium, Dementia, Amnestic, Cognitive Disorders
Duk Lyul NaDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Delirium, Dementia, Amnestic, Cognitive Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sra-333 New York State Psychiatric Institute | Phase 4 | BB |
Intranasal Auto-M2-Bfs Russian Academy of Medical Sciences | Phase 1/2 | CCC |
L-Leucine Washington University School of Medicine | D |
Same molecule, other indications
Neurostem®-Ad is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →